AnaptysBio (ANAB) Competitors $19.60 -0.56 (-2.75%) As of 03:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB vs. TARS, IDYA, OCUL, MLYS, IBRX, DNLI, IRON, BEAM, CNTA, and BLTEShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Denali Therapeutics (DNLI), Disc Medicine (IRON), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Its Competitors Tarsus Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Mineralys Therapeutics ImmunityBio Denali Therapeutics Disc Medicine Beam Therapeutics Centessa Pharmaceuticals Belite Bio AnaptysBio (NASDAQ:ANAB) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends. Does the media prefer ANAB or TARS? In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than AnaptysBio. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 5 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.32 beat Tarsus Pharmaceuticals' score of 0.57 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ANAB or TARS? AnaptysBio has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Do insiders & institutionals hold more shares of ANAB or TARS? 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 33.5% of AnaptysBio shares are held by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate ANAB or TARS? AnaptysBio currently has a consensus price target of $46.13, suggesting a potential upside of 135.27%. Tarsus Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 32.61%. Given AnaptysBio's stronger consensus rating and higher possible upside, equities analysts clearly believe AnaptysBio is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Tarsus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is ANAB or TARS more profitable? Tarsus Pharmaceuticals has a net margin of -31.13% compared to AnaptysBio's net margin of -107.66%. Tarsus Pharmaceuticals' return on equity of -32.36% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-107.66% -366.98% -30.58% Tarsus Pharmaceuticals -31.13%-32.36%-21.04% Which has preferable earnings & valuation, ANAB or TARS? Tarsus Pharmaceuticals has higher revenue and earnings than AnaptysBio. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M6.01-$145.23M-$4.48-4.38Tarsus Pharmaceuticals$295.52M7.18-$115.55M-$2.33-21.58 SummaryTarsus Pharmaceuticals beats AnaptysBio on 10 of the 17 factors compared between the two stocks. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$547.54M$3.10B$5.70B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-4.3621.3675.8126.51Price / Sales6.01386.19492.95166.26Price / CashN/A44.4425.8129.90Price / Book8.419.6112.836.31Net Income-$145.23M-$53.28M$3.28B$270.12M7 Day Performance-11.41%0.44%0.24%2.04%1 Month Performance-2.66%4.68%4.59%6.25%1 Year Performance-49.37%10.08%68.69%25.50% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio2.2836 of 5 stars$19.61-2.8%$46.13+135.3%-50.0%$547.54M$91.28M-4.36100News CoveragePositive NewsAnalyst ForecastTARSTarsus Pharmaceuticals2.5028 of 5 stars$56.89-1.3%$66.67+17.2%+49.1%$2.43B$182.95M-24.4250Positive NewsIDYAIDEAYA Biosciences3.971 of 5 stars$23.39-13.9%$45.77+95.7%-34.5%$2.38B$7M-6.1780High Trading VolumeOCULOcular Therapeutix3.8945 of 5 stars$12.71-6.5%$17.20+35.3%+39.3%$2.37B$63.72M-9.93230News CoveragePositive NewsAnalyst ForecastMLYSMineralys Therapeutics2.8301 of 5 stars$35.93+3.2%$36.60+1.9%+207.9%$2.31BN/A-10.0928IBRXImmunityBio2.5221 of 5 stars$2.41+0.4%$10.75+346.1%-23.5%$2.27B$14.74M-5.02590DNLIDenali Therapeutics4.2964 of 5 stars$15.50+0.5%$33.62+116.9%-57.2%$2.26B$330.53M-5.54430Positive NewsIRONDisc Medicine3.227 of 5 stars$61.91+1.9%$98.30+58.8%+25.3%$2.11BN/A-13.8530Positive NewsHigh Trading VolumeBEAMBeam Therapeutics3.0425 of 5 stars$19.94-4.5%$48.45+143.0%-19.1%$2.11B$63.52M-4.43510Analyst DowngradeCNTACentessa Pharmaceuticals3.14 of 5 stars$18.03+14.6%$31.45+74.5%+29.6%$2.11B$6.85M-10.07200Insider TradeHigh Trading VolumeBLTEBelite Bio2.52 of 5 stars$67.51+2.7%$96.67+43.2%+36.8%$2.09BN/A-43.5510News CoverageAnalyst Forecast Related Companies and Tools Related Companies Tarsus Pharmaceuticals Competitors IDEAYA Biosciences Competitors Ocular Therapeutix Competitors Mineralys Therapeutics Competitors ImmunityBio Competitors Denali Therapeutics Competitors Disc Medicine Competitors Beam Therapeutics Competitors Centessa Pharmaceuticals Competitors Belite Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANAB) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANAB Stock Alerts